Here's some of what is coming soon to NeurologyLive® this week.
|Videos|May 20, 2021
The Ever-Expanding Multiple Sclerosis Therapeutics
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Suma Shah, MD
Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine - S. Mitchell Freedman, MD FAAN
Adjunct Professor of Neurology, University of North Carolina-Chapel Hill
Key Learning Objectives
- Virtual patient visits during COVID-19 when treating MS
- Changing barriers to treating MS
- Evolution of monitoring safety and efficacy of therapy
- The future of treating MS
Advertisement
Related to this article
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.
Here's some of what is coming soon to NeurologyLive® this week.
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Defining Precision Medicine in Multiple Sclerosis
4
The Untapped Promise of Genetics in Multiple Sclerosis
5